Pharma BD Deal Intelligence

Cadrenal Therapeutics, Inc. / Abbott Laboratories

2025 · Co-Development · Complete

Cadrenal Therapeutics entered a collaboration agreement with Abbott Global Enterprises Limited covering Cadrenal's planned Phase 3 warfarin-controlled TECHVAL study of tecarfarin in patients with a left ventricular assist device. Abbott will share LVAD-population data from its MOMENTUM 3 and ARIES HM3 US IDE trials and grants Cadrenal a non-exclusive, limited, non-transferable, non-sublicensable license to use that data for the study, including protocol development support and related regulatory submissions. Cadrenal remains the regulatory sponsor of the study. No financial terms were disclosed in the Form 8-K.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals